Overview
- Inito closed a $29 million Series B led by Bertelsmann India Investments with participation from Fireside Ventures, taking total funding to about $45 million.
- The funding will accelerate R&D on synthetic antibodies designed and virtually screened with AI, with the team reporting promising wet-lab results.
- Its current reader measures FSH, estrogen, LH and PdG on a single strip, with AI models interpreting results from a dataset exceeding 30 million hormone data points since 2021.
- The company plans to scale manufacturing and expand internationally while developing tests for pregnancy, menopause, testosterone, thyroid function, vitamins and metabolic health.
- Inito cites more than 20 patents and teams in Bengaluru, Dubai and London, with Inc42 reporting FY24 revenue growth and a jump in profit to INR 7.7 crore.